Skip to main content
MindWalk Holdings Corp. logo

MindWalk Holdings Corp. — Investor Relations & Filings

Ticker · HYFT ISIN · CA45257F2008 US Professional, scientific and technical activities
Open in API
Filings indexed 256 across all filing types
Latest filing 2021-08-04 Regulatory Filings
Country US United States of America
Listing US HYFT

About MindWalk Holdings Corp.

https://www.ipatherapeutics.com/

MindWalk Holdings Corp. is a Bio-Native AI company that focuses on transforming drug discovery and development. The company operates a biointelligence ecosystem that integrates artificial intelligence, multi-omics data, and advanced laboratory research to make complex biology computable and actionable. This unified platform is designed to accelerate the discovery and development of biologics, including therapeutic antibodies, diagnostics, vaccines, and peptide therapeutics, from target identification through to the clinical stage. Its capabilities are powered by proprietary technologies such as the patented HYFT® technology and the LensAI™ platform, which are adaptable to specific targets, modalities, and program priorities.

Recent filings

Filing Released Lang Actions
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release dated August 4, 2021, but does not contain detailed financial statements or substantive financial data. The document length is short (1392 characters), and it primarily serves as a regulatory filing to report current information rather than a full financial report or earnings release. According to the rules, Form 6-K filings are best classified under Regulatory Filings (RNS) as they are miscellaneous regulatory announcements that do not fit other specific categories.
2021-08-04 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit but does not contain detailed financial statements or substantive financial data. The document length is short (1389 characters), and it primarily serves as a regulatory filing to report information to the SEC. There is no indication that this is an annual report, earnings release, or other detailed financial report. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2021-07-28 English
40-F
Annual Report Classification · 100% confidence The document is a Form 40-F filed with the SEC, which is an annual report for a foreign private issuer. It explicitly states it is an Annual Report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended April 30, 2021. It includes references to audited annual financial statements, management's discussion and analysis, and annual information form. The document contains detailed financial and governance information typical of an annual report. It is not a short announcement or a certification letter, but a full report. Therefore, the appropriate classification is Annual Report (10-K equivalent for foreign issuers).
2021-07-28 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It references a press release dated July 22, 2021, but does not contain detailed financial statements or substantive financial data. The document length is short (1389 characters), and it primarily serves as a regulatory filing to report information pursuant to SEC rules. It does not contain an annual report, earnings release, or other detailed financial or management reports. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2021-07-22 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It is dated July 2021 and includes a press release as an exhibit. The document length is short (1389 characters) and primarily serves as a regulatory filing to report current information rather than a full financial report or detailed presentation. It does not contain financial statements or detailed analysis, nor does it announce voting results, management changes, or capital activities. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories.
2021-07-15 English
IMMUNOPRECISE ANTIBODIES LTD. 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted pursuant to SEC rules. It includes a press release dated June 22, 2021, but the document itself is short (1389 characters) and does not contain detailed financial statements or substantive financial data. It is primarily an announcement filing with an exhibit index referencing a press release. According to the rules, such filings that are brief and serve as announcements or regulatory updates fall under Regulatory Filings (RNS).
2021-06-22 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.